Your browser doesn't support javascript.
loading
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai, Sheng F; Huang, Ying; Lance, Jennie R; Mao, Hsiaoyin Charlene; Dunbar, Andrew J; McNulty, Samantha N; Druley, Todd; Li, Yan; Baer, Maria R; Stock, Wendy; Kovacsovics, Tibor; Blum, William G; Schiller, Gary J; Olin, Rebecca L; Foran, James M; Litzow, Mark; Lin, Tara; Patel, Prapti; Foster, Matthew C; Boyiadzis, Michael; Collins, Robert H; Chervin, Jordan; Shoben, Abigail; Vergilio, Jo-Anne; Heerema, Nyla A; Rosenberg, Leonard; Chen, Timothy L; Yocum, Ashley O; Druggan, Franchesca; Marcus, Sonja; Stefanos, Mona; Druker, Brian J; Mims, Alice S; Borate, Uma; Burd, Amy; Byrd, John C; Levine, Ross L; Stein, Eytan M.
Affiliation
  • Cai SF; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Huang Y; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Lance JR; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Mao HC; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Dunbar AJ; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • McNulty SN; Invitae, San Francisco, CA.
  • Druley T; Invitae, San Francisco, CA.
  • Li Y; Bristol Myers Squibb, New York, NY.
  • Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
  • Stock W; Department of Hematology and Oncology, University of Chicago Medical Center, Chicago, IL.
  • Kovacsovics T; Huntsman Cancer Institute, Salt Lake City, UT.
  • Blum WG; Department of Hematology and Medical Oncology, Emory University, Atlanta, GA.
  • Schiller GJ; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.
  • Olin RL; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Foran JM; Department of Hematology, Mayo Clinic, Jacksonville, FL.
  • Litzow M; Department of Hematology, Mayo Clinic, Rochester, MN.
  • Lin T; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, KS.
  • Patel P; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Foster MC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
  • Boyiadzis M; Division of Hematolog/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
  • Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Chervin J; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Shoben A; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Vergilio JA; Foundation Medicine, Inc, Cambridge, MA.
  • Heerema NA; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Rosenberg L; Leukemia and Lymphoma Society, Rye Brook, NY.
  • Chen TL; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Yocum AO; Leukemia and Lymphoma Society, Rye Brook, NY.
  • Druggan F; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Marcus S; Leukemia and Lymphoma Society, Rye Brook, NY.
  • Stefanos M; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Druker BJ; Knight Cancer Institute, Portland, OR.
  • Mims AS; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Borate U; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Burd A; Leukemia and Lymphoma Society, Rye Brook, NY.
  • Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.
  • Levine RL; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Stein EM; Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood Adv ; 8(2): 429-440, 2024 01 23.
Article in En | MEDLINE | ID: mdl-37871309
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Triazines / Leukemia, Myeloid, Acute / Aminopyridines Limits: Humans Language: En Journal: Blood Adv Year: 2024 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Triazines / Leukemia, Myeloid, Acute / Aminopyridines Limits: Humans Language: En Journal: Blood Adv Year: 2024 Document type: Article Country of publication: Estados Unidos